ABVC BioPharma, Inc.

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Major
MRKMerck & Co., Inc. 1.69%80.840.7%$1589.65m
JNJJohnson & Johnson 0.01%163.880.7%$1030.29m
PFEPfizer Inc. 1.54%42.740.9%$938.39m
ABBVAbbVie, Inc. 0.76%108.261.9%$678.64m
BMYBristol-Myers Squibb Co. 1.07%58.211.0%$660.32m
LLYEli Lilly & Co. 0.46%243.421.1%$609.86m
AZNAstraZeneca Plc 0.75%60.621.0%$366.78m
NVSNovartis AG 1.68%84.550.2%$176.98m
GSKGlaxoSmithKline Plc 0.83%39.500.2%$162.13m
RGENRepligen Corp. 1.87%267.566.8%$117.78m
AVIRAtea Pharmaceuticals, Inc. -3.55%13.330.3%$117.55m
VTRSViatris, Inc. 3.46%14.040.0%$93.13m
NVONovo Nordisk A/S -0.10%104.550.1%$91.60m
EDSAEdesa Biotech, Inc. -1.10%8.130.0%$73.28m
SNYSanofi 2.31%49.170.2%$64.91m

Company Profile

ABVC BioPharma, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of new drugs and medical devices. The company also integrates research achievements from Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center. It conducts clinical trials of translational medicine for Proof of Concept and out-licenses it to international pharmaceutical companies. Its products include BLI-1005 CNS-Major Depressive Disorder; BLI-1008 CNS-Attention Deficit Hyperactivity Disorder; BLI-1401-1 Anti-Tumor Combination Therapy-Solid Tumor with Anti-PD-1; BLI-1401-2 Anti-Tumor Combination Therapy-Triple Negative Breast Cancer; and BLI-1501 Hematology-Chronic Lymphocytic Leukemia. The company was founded in 1990 and is headquartered in Fremont, CA.